Martin Früh

University of Bern — Switzerland

Medicine · Health Sciences

38h-index11.0kcitations208works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(111), Lung Cancer Research Studies(56), Lung Cancer Diagnosis and Treatment(46), Cancer Immunotherapy and Biomarkers(44), Colorectal Cancer Treatments and Studies(32)

Publications206 total

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer·2025Open Access
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open·2025Open Access
Long-term survival in the ALEX trial: a milestone in improving the prognosis of patients with ALK-positive non-small-cell lung cancer
Annals of Oncology·2025Open Access
EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
Journal of Thoracic Oncology·2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clinical Lung Cancer·2025
Test performance of a DNA methylation–based liquid biopsy biomarker for detection and classification of pleural mesothelioma (PM).
Journal of Clinical Oncology·2025
Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report
JTO Clinical and Research Reports·2025Open Access
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
Lung Cancer·2025· 2 cited
Light on the horizon for HER2 overexpressing non-small cell lung cancer?
Translational Lung Cancer Research·2025Open Access
A randomised phase III study of bevacizumab and carboplatin–pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial
Annals of Oncology·2025· 16 citedOpen Access
First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small Cell Lung Cancer (NSCLC) with asymptomatic brain metastases
SSRN Electronic Journal·2025Open Access
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
JCO Oncology Practice·2024· 2 cited
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
JTO Clinical and Research Reports·2024· 4 citedOpen Access
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
JTO Clinical and Research Reports·2024· 5 citedOpen Access
Characterizing the tumor microbiome of non-small cell lung cancer patients receiving neoadjuvant chemo-immunotherapy (SAKK 16/14)
Lung Cancer·2024
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Journal of Clinical Oncology·2024· 28 cited
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
Journal of Clinical Oncology·2024· 13 citedOpen Access
Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma
International Journal of Molecular Sciences·2024· 4 citedOpen Access
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2024Open Access
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade
American Journal of Respiratory and Critical Care Medicine·2024· 5 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Oliver Gautschi(14), Solange Peters(14), Sacha I. Rothschild(13), Miklos Pless(12), Markus Joerger(10), Lukas Flatz(9), Sabine Schmid(8), Alfred Zippelius(8), Stefan Diem(7), Wolfram Jochum(7), Enriqueta Felip(7), Rolf A. Stahel(7), Alessandra Curioni‐Fontecedro(6), Benjamin Besse(6), Patrizia Froesch(6), Dirk Klingbiel(6), Sanjay Popat(5), Julie Milia(5), Enric Carcereny(5), Richard Cathomas(5)